NCT00534456 - An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions

AnemiaCardiovascular DiseaseCongestive Heart FailureHeart FailureVentricular Dysfunction

Interventions

DRUG

Placebo

Placebo group to receive volume and dose frequency changes resembling titration dosing in the treatment group.

DRUG

Darbepoetin alfa

Starting dose: 0.75 mcg/kg subcutaneously Q2W. Subsequent doses: Darbepoetin alfa group to receive darbepoetin alfa titrated to achieve Hb target of 13.0 g/dL, not to exceed 14.5 g/dL.